Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer

The FDA has signed off TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) initiation of a Phase 1/2 trial of YH001 in combination with envafolimab…
byVandana Singh
August 29, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • The FDA has signed off TRACON Pharmaceuticals Inc’s (NASDAQ:TCON) initiation of a Phase 1/2 trial of YH001 in combination with envafolimab and doxorubicin in sarcoma patients, including those who have not received prior therapy.
  • The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma. 
  • Related: TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications.
  • Additionally, the safety and efficacy of YH001, envafolimab, and doxorubicin will be assessed in the more prevalent sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
  • YH001, an IgG1 antibody against CTLA-4, has shown enhanced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. 
  • Price Action: TCON shares are up 0.50% at $2.02 on the last check Monday.
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts